40256-14-2

Basic information

• Product Name: Ethanol, 2-(4-piperidinyloxy)-
• CAS NO: 40256-14-2
• Molecular Formula: C7H15NO2
• Molecular Weight: 145.202
• Mol File: 40256-14-2.mol

Chemical Properties

• CAS DataBase Reference: Ethanol, 2-(4-piperidinyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanol, 2-(4-piperidinyloxy)-(40256-14-2)
• EPA Substance Registry System: Ethanol, 2-(4-piperidinyloxy)-(40256-14-2)

Safety Data

• Hazardous Substances Data: 40256-14-2(Hazardous Substances Data)

Upstream product

• 86450-38-6 2-(pyridin-4-yloxy)ethan-1-ol 
• 108-96-3 4-pyridone 
• 163210-40-0 tert-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate 
• 177-11-7 4,4-ethylenedioxy-piperidine 

Downstream Products

• 1353983-03-5 2-(1-methyl-piperidin-4-yloxy)-ethanol 
• 163210-40-0 tert-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate 
• 1056877-76-9 C₁₄H₂₁N₃O₄ 
• 40255-57-0 10-<3-<4-(2-Hydroxyaethoxy)-piperidino>-propyl>-2-trifluormethyl-phenothiazin 
• 335349-86-5 {5-[4-(2-hydroxy-ethoxy)-piperidin-1-yl]-4-iodo-2-nitro-phenyl}-carbamic acid tert.-butyl ester 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

INDANOL DERIVATIVE

The present invention provides a compound having the following general formula (I) which is useful as a neurokinin receptor antagonist: (wherein, R1, R2: optionally substituted (hetero)aryl, R3: -CO-R4, -CO-O-R4, etc., R4: alkyl, cycloalkyl, etc., A: CH2, CO, SO2, B: a single bond, etc., D: oxygen, CH2, E: alkylene, alkenylene, n: 1 to 3).

Benzoimidazole compounds

Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.

10-(Piperidin o-alkyl)-phenothiazines

Novel 10-(piperidino-alkyl)-phenothiazines of the formula STR1 wherein X is selected from the group consisting of hydrogen, chlorine, --CF3, --OCH3 and SCH3, B and R are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, p is 0 or 1, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR2 and --COR1, R2 is linear alkyl of 1 to 15 carbon atoms and R1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally containing a double bond or --O-- and a polymethoxyphenyl and their non-toxic, pharmaceutically acceptable acid addition salts having neuroleptic, analgesic, spasmolytic and antihistaminic activity and their preparation and novel intermediates.